Vis enkel innførsel

dc.contributor.authorPasternak, Björn
dc.contributor.authorWintzell, Viktor
dc.contributor.authorMellbye, Mads
dc.contributor.authorEliasson, Björn
dc.contributor.authorSvensson, Ann-Marie
dc.contributor.authorFranzén, Stefan
dc.contributor.authorGudbjörnsdóttir, Soffia
dc.contributor.authorHveem, Kristian
dc.contributor.authorJonasson, Christian
dc.contributor.authorSvanström, Henrik
dc.contributor.authorUeda, Peter
dc.date.accessioned2021-02-15T08:13:39Z
dc.date.available2021-02-15T08:13:39Z
dc.date.created2020-06-09T14:51:47Z
dc.date.issued2020
dc.identifier.citationBMJ (Clinical Research Edition). 2020, 369 .en_US
dc.identifier.issn0959-8138
dc.identifier.urihttps://hdl.handle.net/11250/2727946
dc.description.abstractOBJECTIVE To assess the association between use of sodiumglucose co-transporter 2 (SGLT2) inhibitors and risk of serious renal events in data from routine clinical practice. DESIGN Cohort study using an active comparator, new user design and nationwide register data. SETTING Sweden, Denmark, and Norway, 2013-18. PARTICIPANTS Cohort of 29 887 new users of SGLT2 inhibitors (follow-up time: dapagliflozin 66.1%; empagliflozin 32.6%; canagliflozin 1.3%) and 29 887 new users of an active comparator, dipeptidyl peptidase-4 inhibitors, matched 1:1 on the basis of a propensity score with 57 variables. Mean follow-up time was 1.7 (SD 1.0) years. EXPOSURES SGLT2 inhibitors versus dipeptidyl peptidase-4 inhibitors, defined by filled prescriptions and analysed according to intention to treat. MAIN OUTCOME MEASURES The main outcome was serious renal events, a composite including renal replacement therapy, death from renal causes, and hospital admission for renal events. Secondary outcomes were the individual components of the main outcome. RESULTS The mean age of the study population was 61.3 (SD 10.5) years; 11 108 (19%) had cardiovascular disease, and 1974 (3%) had chronic kidney disease. Use of SGLT2 inhibitors, compared with dipeptidylen_US
dc.language.isoengen_US
dc.publisherBMJen_US
dc.rightsNavngivelse-Ikkekommersiell 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/deed.no*
dc.titleUse of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort studyen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.source.pagenumber9en_US
dc.source.volume369en_US
dc.source.journalBMJ (Clinical Research Edition)en_US
dc.identifier.doi10.1136/bmj.m1186
dc.identifier.cristin1814595
dc.relation.projectStiftelsen Kristian Gerhard Jebsen: SKGJ-MED-015en_US
dc.relation.projectNorges forskningsråd: 248817en_US
dc.description.localcodeDenne artikkelen er Open Access, publisert under vilkårene for en Creative Commons-lisens. Se tilbake til artikkelen for å sjekke gjeldende lisens (detaljer er i artikkelen Fotnoter). Artikler publisert under CC-BY-NC tillater ikke-kommersiell bruk, distribusjon og reproduksjon i hvilket som helst medium, forutsatt at det originale arbeidet er sitert riktig. Tillatelse trenger bare å oppnås for kommersiell bruk og kan gjøres via RightsLink-systemet nedenfor. Artikler publisert under CC-BY tillater ubegrenset bruk, distribusjon og reproduksjon i hvilket som helst medium, forutsatt at det opprinnelige verket er riktig sitert.en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse-Ikkekommersiell 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse-Ikkekommersiell 4.0 Internasjonal